GILD · Gilead Sciences, Inc.
$130.86
+0.50% last session
End-of-day data · updated 2026-07-25
Market cap
$161B
Enterprise value
$173B
Trailing P/E
17.6
Forward P/E
13.4
Dividend yield
3.0%
Beta
0.34
Avg volume
8M
Employees
17K
2D change
-1.18%
5D change
-2.93%
10D change
-1.81%
30D change
4.42%
60D change
-2.67%
MTD change
2.65%
YTD change
6.65%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GILD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-27
Latest call per bank · past 12 months
Morgan Stanley
Overweight$165
+26.1% vs priceRBC Capital
Sector Perform$120
-8.3% vs priceHSBC
Buy$155
+18.4% vs priceCitigroup
Buy$165
+26.1% vs priceJefferies
Buy$180
+37.6% vs priceBarclays
Equal-Weight$155
+18.4% vs priceWells Fargo
Overweight$165
+26.1% vs priceUBS
Buy$155
+18.4% vs priceJP Morgan
Overweight$150
+14.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-27 | Morgan Stanley | Maintains | Overweight | $166 → $165 |
| 2026-07-21 | Leerink Partners | Downgrade | Outperform → Market Perform | $146 → $127 |
| 2026-07-08 | Morgan Stanley | Maintains | Overweight | $168 → $166 |
| 2026-07-07 | RBC Capital | Maintains | Sector Perform | $122 → $120 |
| 2026-07-07 | Truist Securities | Maintains | Buy | $157 → $156 |
| 2026-07-06 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 2026-07-06 | HSBC | Upgrade | Hold → Buy | $133 → $155 |
| 2026-06-16 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.7% above the 50-day MA ($129.32).
- Price vs 200-day MA: Trading 1.1% above the 200-day MA ($130.10).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.16) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($107.48) and high ($153.91).
GILD Price Chart
Loading chart for GILD…
Fundamentals
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.